1

Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma

xbyaowlwu0ql4
Abstract Background Patients with multiple myeloma (MM) were excluded from the original SARS-CoV-2 mRNA vaccine trials. which may influence vaccine hesitancy in this population. We prospectively characterized the safety and immunogenicity of two-dose SARS-CoV-2 mRNA vaccination in 44 patients with MM. who underwent vaccination from 12/17/2020 to 3/18/2021. https://www.wholisticpet.shop/product-category/feline-litter-supplies/
Report this page

Comments

    HTML is allowed

Who Upvoted this Story